The enzyme myristoyl-CoA:protein N-myristoyltransferase (NMT) has recently been validated as a promising drug target in trypanosomiasis (Frearson et al., 2010) and malaria (Wright et al., 2014), diseases caused by the protozoan parasites Trypanosoma brucei and species of Plasmodium, respectively. Here, NMT1 is linked to malaria.